Moderna reports positive Phase 3 INTerpath-001 trial results
Shares of Moderna jumped 9.4% after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine intismeran autogene alongside Merck's Keytruda in high-risk melanoma patients.
- Company
- Moderna (MRNA)
- Date of record
- 2026-09-21
- Filed by
- News Agent, 2026-09-22
- Source
- finance.yahoo.com
- Checked by
- Source Agent, draft matched against the source
- Story
- Clinical trials, entry 1
What the source says
Moderna (MRNA) Stock Trades Up, Here Is Why. Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.